The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Open accessAbstract
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States. The prostate is a hormone-dependent gland in which androgen hormones testosterone and dihydrotestosterone bind to and activate the androgen receptor, initiating nuclear translocation of androgen receptor and a subsequent signaling cascade. Due to the androgen dependency of the prostate, androgen deprivation therapies have emerged as first line treatment for aggressive prostate cancer. Such therapies are effective until the point at which prostate cancer, through a variety of mechanisms including but not limited to generation of ligand-independent androgen receptor splice variants, or intratumoral androgen production, overcome hormone deprivation. These cancers are androgen ablation resistant, clinically termed castration resistant prostate cancer (CRPC) and remain incurable. First-generation antiandrogens established androgen receptor blockade as a therapeutic strategy, but these therapies do not completely block androgen receptor activity. Efficacy and potency have been improved by the development of second-generation antiandrogen therapies, which remain the standard of care for patients with CRPC. Four second-generation anti-androgens are currently approved by the Food and Drug Administration (FDA); abiraterone acetate, enzalutamide, and recently approved apalutamide and darolutamide. This review is intended to provide a thorough overview of FDA approved second-generation antiandrogen discovery, treatment application, strategies for combination therapy to overcome resistance, and an insight for the potential future approaches for therapeutic inhibition of androgen receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 14×
“Further, other studies have followed AR-V7 levels in circulating tumor cells of metastatic CRPC patients and correlated with risk of recurrence, with follow-up PSA serum levels (80).”
BackgroundInfluentialHuggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Huggins, C., & Hodges, C. V. (1972) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.4.232 · Cited by 1,320
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Cloning of Human Androgen Receptor Complementary DNA and Localization to the X Chromosome
Lubahn, D. B., Joseph, D. R., Sullivan, P. M., Willard, H. F., French, F. S., & Wilson, E. M. (1988) · Science · doi:10.1126/science.3353727 · Cited by 1,016
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.
Loose, D. S., Kan, P. B., Hirst, M. A., Marcus, R. A., & Feldman, D. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110903 · Cited by 443
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., Soule, H., Clarke, N. W., Collette, L., Dignam, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9987 · Cited by 433
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30860-x · Cited by 413
Zhou, Z. X. (1995) · Molecular Endocrinology · doi:10.1210/me.9.2.208 · Cited by 411
Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690684 · Cited by 409
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 396
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Sharp, A., Coleman, I., Yuan, W., Sprenger, C., Dolling, D., Rodrigues, D. N., Russo, J. W., Figueiredo, I., Bertan, C., Seed, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122819 · Cited by 393
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene
Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., Jackson, R., Southgate, C., Singh, R., Falconer, A., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345310 · Cited by 366
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 359
Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C. T., Evans, C. P., & Gao, A. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3296 · Cited by 348
Knezevic, D., Goddard, A. D., Natraj, N., Cherbavaz, D. B., Clark-Langone, K. M., Snable, J., Watson, D., Falzarano, S. M., Magi-Galluzzi, C., Klein, E. A., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-690 · Cited by 339
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A., & de Bono, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 329
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293
Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., & Wongvipat, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901488g · Cited by 266
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
Rathkopf, D. E., Morris, M. J., Fox, J. J., Danila, D. C., Slovin, S. F., Hager, J. H., Rix, P. J., Chow Maneval, E., Chen, I., Gönen, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1684 · Cited by 261
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2015) · Nature · doi:10.1038/nature14406 · Cited by 256
Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy
Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L., & Engleman, E. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7150 · Cited by 252
Smith, M., De Bono, J., Sternberg, C., Le Moulec, S., Oudard, S., De Giorgi, U., Krainer, M., Bergman, A., Hoelzer, W., De Wit, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5597 · Cited by 249
Taneja, S. S. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.02.070 · Cited by 228
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Njar, V. C. O., & Brodie, A. M. H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501239f · Cited by 200
Fizazi, K., Massard, C., Bono, P., Jones, R., Kataja, V., James, N., Garcia, J. A., Protheroe, A., Tammela, T. L., Elliott, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70240-2 · Cited by 196
Emerging Variants of Castration-Resistant Prostate Cancer
Vlachostergios, P. J., Puca, L., & Beltran, H. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0593-6 · Cited by 194
Chen, E. J., Sowalsky, A. G., Gao, S., Cai, C., Voznesensky, O., Schaefer, R., Loda, M., True, L. D., Ye, H., Troncoso, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1220 · Cited by 182
Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M.-E., & collaborators, O. B. O. T. P. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9827 · Cited by 173
Localization of functional domains in the androgen receptor
MacLean, H. E., Warne, G. L., & Zajac, J. D. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00049-6 · Cited by 162
Fizazi, K. S., Jones, R. J., Oudard, S. M., Efstathiou, E., Fred Saad, C., de Wit, R., Bono, J. S. D., Cruz, F. M., Fountzilas, G., Ulys, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5119 · Cited by 156
Alterations of androgen receptor in prostate cancer
Linja, M. J., & Visakorpi, T. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.012 · Cited by 154
Androgen deprivation and immunotherapy for the treatment of prostate cancer
Gamat, M., & McNeel, D. G. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0145 · Cited by 153
Schweizer, M. T., Haugk, K. L., McKiernan, J. S., Gulati, R., Cheng, H. H., Maes, J. L., Dumpit, R. F., Nelson, P. S., Montgomery, B., McCune, J. S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198389 · Cited by 138
Wu, B. J., Yin, L., Shi, C., Li, Q., Duan, P., Huang, J.-M., Liu, C., Wang, F., Lewis, M. S., Wang, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.003 · Cited by 135
Smith, M. R., Antonarakis, E. S., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., Alumkal, J. J., Higano, C. S., Maneval, E. C., Bandekar, R. R., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.023 · Cited by 134
Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5 -Reductase
Wright, A. S., Douglas, R. C., Thomas, L. N., Lazier, C. B., & Rittmaster, R. S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7039 · Cited by 128
Harris, K. A., WEINBERG, V. K., Bok, R., Derynck, M. K., & Small, E. J. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64675-7 · Cited by 117
TOMBAL, B. F., Fred Saad, C., Penson, D. F., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C., & Attard, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30898-2 · Cited by 109
Liu, C., Armstrong, C. M., Zhu, Y., Lou, W., & Gao, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.8493 · Cited by 104
Rathkopf, D. E., Smith, M. R., Ryan, C. J., Berry, W. R., Shore, N. D., Liu, G., Higano, C. S., Alumkal, J. J., Hauke, R., Tutrone, R. F., Jr., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx283 · Cited by 102
Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
Mostaghel, E. A., Montgomery, B., & Nelson, P. S. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.016 · Cited by 94
Evans, C. P., Higano, C. S., Keane, T. E., Andriole, G. L., Fred Saad, C., Iversen, P., Miller, K., Kim, C., Kimura, G., Armstrong, A. J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.03.017 · Cited by 92
Small, E. J., Lance, R. S., Gardner, T. A., Karsh, L. I., Fong, L. H., McCoy, C., DeVries, T. A., Sheikh, N. A., GuhaThakurta, D., Chang, N. N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0079 · Cited by 89
Rathkopf, D. E., Antonarakis, E. S., Shore, N. D., Tutrone, R. F., Jr., Alumkal, J. J., Ryan, C. J., Saleh, M. N., Hauke, R. J., Bandekar, R. R., Maneval, E. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2509 · Cited by 89
Fizazi, K. S., Smith, M. R., & TOMBAL, B. F. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.017 · Cited by 85
Ardiani, A., Farsaci, B., Rogers, C. J., Protter, A., Guo, Z., King, T. H., Apelian, D., & Hodge, J. W. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1026 · Cited by 83
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Fizazi, K. S., Albiges, L. K., Loriot, Y., & Massard, C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1081566 · Cited by 74
Liao, C., Lin, T., Li, P., Geary, L., Chen, K., Vaikari, V. P., Wu, B. J., Lin, C., Gross, M. E., & Shih, J. C. (2018) · Oncogene · doi:10.1038/s41388-018-0325-x · Cited by 73
Gaur, S., Gross, M. E., Liao, C., Qian, B., & Shih, J. C. (2019) · The Prostate · doi:10.1002/pros.23774 · Cited by 72
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
Bryce, A. H., & Ryan, C. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.275 · Cited by 70
Mendieta, M. A. E. P., Negri, M., Jagusch, C., Müller‐Vieira, U., Lauterbach, T., & Hartmann, R. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800355c · Cited by 69
Farah, E., Li, C., Cheng, L., Kong, Y., Lanman, N. A., Pascuzzi, P. E., Lorenz, G. R., Zhang, Y., Ahmad, N., Li, L., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006983 · Cited by 67
Miller, K., Carles, J., Gschwend, J. E., Poppel, H. V., Diels, J., & Brookman-May, S. D. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.035 · Cited by 66
Massard, C., Penttinen, H., Vjaters, E., Bono, P., Lietuvietis, V., Tammela, T. L. J., Vuorela, A., Nykänen, P., Pohjanjousi, P., Snapir, A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.046 · Cited by 65
Schweizer, M. T., & Antonarakis, E. S. (2012) · Therapeutic Advances in Urology · doi:10.1177/1756287212452196 · Cited by 63
Knudsen, K. E., & Kelly, W. K. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.33 · Cited by 61
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth
Mohamed, A. A. M., Xavier, C. P., Sukumar, G., Tan, S., Ravindranath, L., Seraj, N., Kumar, V., Sreenath, T., McLeod, D. G., Petrovics, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2949 · Cited by 61
Self-citationRice, M. A., Hsu, E., Aslan, M., Ghoochani, A., Su, A., & Stoyanova, T. I. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0804 · Cited by 60
Self-citationZurth, C., Sandmann, S., Trummel, D., Seidel, D., & Gieschen, H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.345 · Cited by 46
Brawer, M. K. (2000) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(200001/02)18:1<52::aid-ssu8>3.0.co;2-6 · Cited by 42
Mohamed, A. A. M., Tan, S., Xavier, C. P., Katta, S., Huang, W., Ravindranath, L., Jamal, M., Li, H., Srivastava, M., Srivatsan, E. S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0058 · Cited by 41
Cui, J., Wang, Y., Dong, B., Qin, L., Wang, C., Zhou, P., Wang, X., Xu, H., Xue, W., Fang, Y., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31346 · Cited by 40
Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer
Danquah, M. K., Duke, C. B., Patil, R., Miller, D. D., & Mahato, R. I. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0737-1 · Cited by 38
Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
Attard, G., Reid, A. H. M., & de Bono, J. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5170 · Cited by 35
Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F. M., Пили, Р., Stephenson, J., Vogelzang, N. J., Morrison, J. P., & Taplin, M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4665 · Cited by 34
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α‐reductase
Vis, A. N., & Schröder, F. H. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08743.x · Cited by 32
Kwilas, A. R., Ardiani, A., Dirmeier, U., Wottawah, C. M., Schlom, J., & Hodge, J. W. (2015) · Oncotarget · doi:10.18632/oncotarget.4442 · Cited by 27
Mortezavi, A., Salemi, S., Kranzbühler, B., Gross, O., Sulser, T., Simon, H., & Eberli, D. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2385-5 · Cited by 26
Fizazi, K. S., Massard, C., Bono, P., Kataja, V. V., James, N. D., Tammela, T. L. J., Joensuu, H., Aspegrén, J., & Mustonen, M. V. J. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.01.010 · Cited by 21
Wang, X., Huang, Y., Christie, A. L., Bowden, M., Lee, G. M., Kantoff, P. W., & Sweeney, C. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0824 · Cited by 19
Exploring the Role of Enzalutamide in Combination with Radiation Therapy: AnIn VitroStudy
Triggiani, L., Colosini, A., Buglione, M., Pasinetti, N., Orizio, F., Bardoscia, L., Borghetti, P., Maddalo, M., Spiazzi, L., Magrini, S. M., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12619 · Cited by 10
Choudhury, A. D., Gray, K. P., Supko, J. G., Harshman, L. C., Taplin, M., Pace, A. F., Farina, M. S., Zukotynski, K., Bernard, B. D., Kantoff, P. W., et al. (2018) · The Prostate · doi:10.1002/pros.23662 · Cited by 5
Cited by
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras
Samarasinghe, K. T. G., Jaime-Figueroa, S., Burgess, M., Nalawansha, D. A., Dai, K., Hu, Z., Bebenek, A., Holley, S. A., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.011 · Cited by 182
Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
Ben-Batalla, I., Vargas-Delgado, M. E., von Amsberg, G., Janning, M., & Loges, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01184 · Cited by 149
“Finally, galeteronel is the only compound with dual androgen antagonist and biosynthesis inhibitor function, but is still pending approval [Figure 2; (116, 118)].”
Background
Metadata
- Authors
- Rice, M. A., Malhotra, S. V., & Stoyanova, T.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2019-08-28
- Volume
- 9
- Pages
- 801-801
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2966112499
- Cited by
- 309
- References
- 120
- FWCI
- 24.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.